MX2021002070A - Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla. - Google Patents

Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla.

Info

Publication number
MX2021002070A
MX2021002070A MX2021002070A MX2021002070A MX2021002070A MX 2021002070 A MX2021002070 A MX 2021002070A MX 2021002070 A MX2021002070 A MX 2021002070A MX 2021002070 A MX2021002070 A MX 2021002070A MX 2021002070 A MX2021002070 A MX 2021002070A
Authority
MX
Mexico
Prior art keywords
fabry disease
methods
mutation
patients
galactosidase
Prior art date
Application number
MX2021002070A
Other languages
English (en)
Spanish (es)
Inventor
Elfrida Benjamin
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65279726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002070(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2021002070A publication Critical patent/MX2021002070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021002070A 2018-08-20 2019-01-16 Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla. MX2021002070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719962P 2018-08-20 2018-08-20
PCT/US2019/013761 WO2020040806A1 (en) 2018-08-20 2019-01-16 Methods of treating fabry disease in patients having a mutation in the gla gene

Publications (1)

Publication Number Publication Date
MX2021002070A true MX2021002070A (es) 2021-07-15

Family

ID=65279726

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002070A MX2021002070A (es) 2018-08-20 2019-01-16 Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla.
MX2024008350A MX2024008350A (es) 2018-08-20 2021-02-19 Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024008350A MX2024008350A (es) 2018-08-20 2021-02-19 Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.

Country Status (25)

Country Link
US (2) US12594268B2 (cg-RX-API-DMAC7.html)
EP (7) EP3840753B1 (cg-RX-API-DMAC7.html)
JP (3) JP2021535107A (cg-RX-API-DMAC7.html)
KR (3) KR102982790B1 (cg-RX-API-DMAC7.html)
CN (1) CN112888439A (cg-RX-API-DMAC7.html)
AU (2) AU2019326252A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003137A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110065A1 (cg-RX-API-DMAC7.html)
CL (3) CL2021000435A1 (cg-RX-API-DMAC7.html)
DK (1) DK3840753T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190569A1 (cg-RX-API-DMAC7.html)
ES (1) ES2993833T3 (cg-RX-API-DMAC7.html)
FI (1) FI3840753T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241454T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068783T2 (cg-RX-API-DMAC7.html)
IL (2) IL325185A (cg-RX-API-DMAC7.html)
LT (1) LT3840753T (cg-RX-API-DMAC7.html)
MX (2) MX2021002070A (cg-RX-API-DMAC7.html)
PL (1) PL3840753T3 (cg-RX-API-DMAC7.html)
PT (1) PT3840753T (cg-RX-API-DMAC7.html)
RS (1) RS66094B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101117QA (cg-RX-API-DMAC7.html)
SI (1) SI3840753T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400436T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020040806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
CN113969313A (zh) * 2021-11-29 2022-01-25 百世诺(北京)医学检验实验室有限公司 罕见遗传病突变基因及其应用
CN116656704B (zh) * 2023-06-01 2024-11-05 华东理工大学 用于治疗法布里病的转基因表达盒
CN116622750B (zh) * 2023-06-01 2024-05-31 上海勉亦生物科技有限公司 优化的人法布里转基因表达盒及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PL2027137T3 (pl) 2005-06-08 2015-08-31 Amicus Therapeutics Inc Oczyszczanie imino- i aminocukrów
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
EP2435459B1 (en) 2009-05-26 2016-05-04 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase
EP2502068B1 (en) 2009-11-17 2016-02-10 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
WO2012125402A2 (en) 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
WO2013091897A1 (en) 2011-12-22 2013-06-27 Centogene Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc ALPHA GALACTOSIDASE A AND 1-DEOXYGALACTONO JIRIMYCIN CO FORMULATION
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
EP3432882B1 (en) 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EA202090242A1 (ru) 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
AU2019217603A1 (en) 2018-02-06 2020-09-24 Amicus Therapeutics, Inc. Treatment of patients with classic Fabry disease
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
TW202042812A (zh) * 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
US20220313670A1 (en) 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
HRP20260399T1 (hr) * 2020-02-10 2026-05-08 Amicus Therapeutics, Inc. Postupci liječenja fabryjeve bolesti
FI4114390T3 (fi) * 2020-03-06 2025-03-07 Amicus Therapeutics Inc Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä

Also Published As

Publication number Publication date
MX2024008350A (es) 2024-07-19
IL280961A (en) 2021-04-29
SMT202400436T1 (it) 2024-11-15
EP3840753B1 (en) 2024-07-24
KR102982790B1 (ko) 2026-06-26
CL2021000435A1 (es) 2021-10-22
EP3840753A1 (en) 2021-06-30
KR20210046729A (ko) 2021-04-28
IL325185A (en) 2026-02-01
WO2020040806A1 (en) 2020-02-27
KR20240017128A (ko) 2024-02-06
CA3110065A1 (en) 2020-02-27
SI3840753T1 (sl) 2025-01-31
FI3840753T3 (fi) 2024-10-30
HUE068783T2 (hu) 2025-01-28
CN112888439A (zh) 2021-06-01
AU2019326252A1 (en) 2021-02-25
BR112021003137A2 (pt) 2021-05-11
EP4289476A2 (en) 2023-12-13
IL280961B1 (en) 2026-01-01
EP4282472A2 (en) 2023-11-29
JP2021535107A (ja) 2021-12-16
EA202190569A1 (ru) 2021-06-01
JP2025165955A (ja) 2025-11-05
EP4289476A3 (en) 2024-02-21
EP4285991A3 (en) 2024-02-21
CL2024000741A1 (es) 2024-10-04
DK3840753T3 (da) 2024-10-28
KR102982792B1 (ko) 2026-06-25
EP4285990A3 (en) 2024-02-21
EP4299117A2 (en) 2024-01-03
JP2023106398A (ja) 2023-08-01
EP4285990A2 (en) 2023-12-06
EP4285991A2 (en) 2023-12-06
PL3840753T3 (pl) 2025-01-20
LT3840753T (lt) 2024-11-11
EP4299117A3 (en) 2024-02-21
PT3840753T (pt) 2024-10-30
US20240277687A1 (en) 2024-08-22
KR20240017127A (ko) 2024-02-06
EP4282472A3 (en) 2024-02-21
AU2025205141A1 (en) 2025-07-31
US12594268B2 (en) 2026-04-07
ES2993833T3 (en) 2025-01-10
RS66094B1 (sr) 2024-11-29
IL280961B2 (en) 2026-05-01
EP4289475A2 (en) 2023-12-13
SG11202101117QA (en) 2021-03-30
JP7784398B2 (ja) 2025-12-11
EP4289475A3 (en) 2024-02-21
CL2024000739A1 (es) 2024-10-04
HRP20241454T1 (hr) 2024-12-20
US20210315875A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
CO2022002638A2 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla
CL2024000741A1 (es) Métodos para tratar fabry en pacientes con una mutación en el gen gla
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
AR105712A1 (es) Composiciones de insulina de rápida acción
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
BR112017002741A2 (pt) peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2022002423A1 (es) Métodos para tratar la enfermedad de fabry
BR112016017478A2 (pt) novos tratamentos
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
AR122298A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
BR112022009522A2 (pt) Métodos de administração de voxelotor
AR111971A1 (es) Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
AR109102A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR099490A1 (es) Métodos terapéuticos en los que se emplea noribogaína y compuestos relacionados